Holding(s) in Company

DXS INTERNATIONAL PLC

Holding in Company and Total Voting Rights

The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification under the DTR that following the Placing announced on 17 May 2023, the following persons have voting rights in the Company as follows:

3. Details of person subject to the notification obligation iv
Name			Foresight Group LLP
City and country of registered office (if applicable)			London, UK
4. Full name of shareholder(s) (if different from 3.) v
Name			Thames Ventures VCT 1 plc
City and country of registered office (if applicable)			London, UK
5. Date on which the threshold was crossed or reached vi:			24.05.23
6. Date on which issuer notified (DD/MM/YYYY):			24.05.23
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached	11.71	11.71			7,500,000
Position of previous notification (if applicable)	n/a	n/a		n/a

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)	Number of voting rights ix		% of voting rights
	Direct (DTR5.1)	Indirect (DTR5.2.1)	Direct (DTR5.1)	Indirect (DTR5.2.1)
GB00B2Q6HZ92	7,500,000	n/a	11.71	n/a
SUBTOTAL 8. A	7,500,000		11.71

In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 24 May 2023 the Company's issued share capital consists of 64,022,124 Ordinary Shares of 0.33pence each, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 64,022,124.

The above figure of 64,022,124 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of DXS International plc accept responsibility for this announcement

Enquiries:

David Immelman      (Chief Executive) DXS International plc	01252 719800 [e-mail]
Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS
www.dxs-systems.co.uk

Corporate Advisor
David Papworth City & Merchant	0207 101 7676

Corporate Broker
Hybridan LLP Claire Louise Noyce	020 3764 2341

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.